Cleveland Biolabs, Inc Overview
Company Headquarters: New York, US
Founded: 2003
Workforce: ~150
Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.
Strategy
Cleveland Biolabs, Inc. is currently focusing on developing innovative products for diseases such as cancer, autoimmune disease, infectious disease, and inflammatory disease. It is also focusing on the AIMS Program to produce next-generation immune therapies. Furthermore, it has partnerships with government agencies that are investing in its biodefense product development to meet emergency needs
